IL274010B2 - Thiones converted to phenylsulfonyl, phenyltriazole and their uses - Google Patents

Thiones converted to phenylsulfonyl, phenyltriazole and their uses

Info

Publication number
IL274010B2
IL274010B2 IL274010A IL27401020A IL274010B2 IL 274010 B2 IL274010 B2 IL 274010B2 IL 274010 A IL274010 A IL 274010A IL 27401020 A IL27401020 A IL 27401020A IL 274010 B2 IL274010 B2 IL 274010B2
Authority
IL
Israel
Prior art keywords
4alkyl
compound
pharmaceutically acceptable
phenyl
acceptable salt
Prior art date
Application number
IL274010A
Other languages
English (en)
Hebrew (he)
Other versions
IL274010A (en
IL274010B1 (en
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of IL274010A publication Critical patent/IL274010A/en
Publication of IL274010B1 publication Critical patent/IL274010B1/en
Publication of IL274010B2 publication Critical patent/IL274010B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL274010A 2017-10-30 2020-04-16 Thiones converted to phenylsulfonyl, phenyltriazole and their uses IL274010B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579070P 2017-10-30 2017-10-30
US201762584630P 2017-11-10 2017-11-10
PCT/US2018/058050 WO2019089478A1 (en) 2017-10-30 2018-10-29 Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof

Publications (3)

Publication Number Publication Date
IL274010A IL274010A (en) 2020-05-31
IL274010B1 IL274010B1 (en) 2023-03-01
IL274010B2 true IL274010B2 (en) 2023-07-01

Family

ID=66333645

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274010A IL274010B2 (en) 2017-10-30 2020-04-16 Thiones converted to phenylsulfonyl, phenyltriazole and their uses

Country Status (12)

Country Link
US (4) US10501423B2 (en:Method)
EP (1) EP3703675A4 (en:Method)
JP (2) JP7277473B2 (en:Method)
KR (1) KR102639231B1 (en:Method)
CN (1) CN111372579B (en:Method)
AU (1) AU2018359224B2 (en:Method)
BR (1) BR112020008727A2 (en:Method)
CA (1) CA3080578A1 (en:Method)
IL (1) IL274010B2 (en:Method)
MX (1) MX2020004202A (en:Method)
SG (1) SG11202003879RA (en:Method)
WO (1) WO2019089478A1 (en:Method)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102639231B1 (ko) 2017-10-30 2024-02-22 뉴로포레 테라피스, 인코포레이티드 치환된 페닐 설폰일 페닐 트리아졸 싸이온 및 이의 용도
CN112512523A (zh) * 2018-06-20 2021-03-16 神经孔疗法股份有限公司 使用oat3的抑制剂治疗与神经退行性病变相关的病状的方法
CN117384029B (zh) * 2023-12-12 2024-02-20 山东国邦药业有限公司 一种2,4,5-三氟苯乙酸的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
US4279637A (en) 1979-06-02 1981-07-21 Velsicol Chemical Corporation Herbicidal N-substituted 4-imidazolin-2-ones
DE3307506A1 (de) 1983-03-03 1984-09-06 Agfa-Gevaert Ag, 5090 Leverkusen Fotografisches aufzeichnungsmaterial mit inhibitorvorlaeuferverbindungen
US5108486A (en) * 1990-02-09 1992-04-28 Kanagawa Chemical Laboratory, Ltd. Herbicidal substituted-phenyl-1,2,4-triazol-5(1H)-thiones and -ones
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
DE10123586A1 (de) 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
US20020183306A1 (en) 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
RU2223952C2 (ru) 2001-06-04 2004-02-20 Институт физиологически активных веществ РАН Производные n,s-замещенных n'-1-[(гетеро)арил]-n'-[(гетеро)арил]метилизотиомочевин или их солей с фармакологически приемлемыми кислотами нх, способы получения их солей и оснований, фармацевтическая композиция, способ лечения и способ изучения глутаматэргической системы
EP2168576A3 (en) 2001-09-14 2010-05-26 Shionogi & Co., Ltd. Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
CA2530538A1 (en) 2003-07-09 2005-01-20 Keith Roger Bley Thiophenylaminoimidazolines as prostaglandin i2 antagonists
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
US20050228031A1 (en) 2004-04-13 2005-10-13 Bilodeau Mark T Tyrosine kinase inhibitors
US7008748B1 (en) * 2004-09-07 2006-03-07 Eastman Kodak Company Silver salt-toner co-precipitates and imaging materials
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US20060217390A1 (en) 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
CN101247807A (zh) 2005-05-09 2008-08-20 艾其林医药公司 噻唑化合物及使用方法
US20060276464A1 (en) 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
JP2009500351A (ja) 2005-07-04 2009-01-08 ドクター レディズ ラボラトリーズ リミテッド Ampkアクチベータとしてのチアゾール誘導体
SI2013204T1 (sl) 2006-03-24 2015-06-30 Array Biopharma, Inc. Analogi 2-aminopriridina kot aktivatorji glukokinaze
KR20090079259A (ko) * 2006-11-09 2009-07-21 에프. 호프만-라 로슈 아게 5-ht6 억제제로서 아릴설폰일 피롤리딘
WO2008078100A2 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
JP5450108B2 (ja) 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての2−アミノピリジン類似体
EP2573087A1 (en) 2007-09-21 2013-03-27 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
PE20091315A1 (es) 2008-01-09 2009-09-21 Array Biopharma Inc Ciclopentanos de pirimidilo como inhibidores de la proteina cinasa akt
WO2009117444A1 (en) 2008-03-17 2009-09-24 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
TWI488841B (zh) 2009-03-27 2015-06-21 Hitachi Chemical Co Ltd A thermosetting resin composition, and an insulating film, a laminate, and a printed wiring board
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピラジン
CN103270023B (zh) * 2010-09-03 2016-11-02 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物
WO2013123061A1 (en) 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EP2852589B1 (en) 2012-05-22 2021-04-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
US20140044813A1 (en) * 2012-08-09 2014-02-13 Kemin Industries, Inc. Plant Extracts for Improving Cognitive Health and Function
HK1206331A1 (en) * 2012-08-09 2016-01-08 Neuropore Therapies, Inc. Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗-cd19嵌合抗原受體治療癌症
KR102639231B1 (ko) * 2017-10-30 2024-02-22 뉴로포레 테라피스, 인코포레이티드 치환된 페닐 설폰일 페닐 트리아졸 싸이온 및 이의 용도

Also Published As

Publication number Publication date
SG11202003879RA (en) 2020-05-28
WO2019089478A1 (en) 2019-05-09
US11708338B2 (en) 2023-07-25
CN111372579B (zh) 2023-08-22
KR102639231B1 (ko) 2024-02-22
AU2018359224A1 (en) 2020-06-18
KR20200083545A (ko) 2020-07-08
CA3080578A1 (en) 2019-05-09
US20200123116A1 (en) 2020-04-23
CN111372579A (zh) 2020-07-03
JP7277473B2 (ja) 2023-05-19
MX2020004202A (es) 2020-08-13
BR112020008727A2 (pt) 2020-10-20
IL274010A (en) 2020-05-31
US20210300881A1 (en) 2021-09-30
JP2021501202A (ja) 2021-01-14
EP3703675A1 (en) 2020-09-09
US20190292158A1 (en) 2019-09-26
JP2023100842A (ja) 2023-07-19
EP3703675A4 (en) 2021-06-16
US20230391734A1 (en) 2023-12-07
US10501423B2 (en) 2019-12-10
US11008294B2 (en) 2021-05-18
IL274010B1 (en) 2023-03-01
AU2018359224B2 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
EP3099684B1 (en) Heteroaryl amides as inhibitors of protein aggregation
US10913735B2 (en) Bis-heteroaryl derivatives as modulators of protein aggregation
US20230391734A1 (en) Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
EP2830608B1 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
EP3810133A1 (en) Method of treating a condition associated with neurodegeneration using inhibitors of oat3
EA042432B1 (ru) Замещенные фенилсульфонил фенилтриазолтионы и их применение
WO2016040780A1 (en) Aminomethyl- and methyloxy-linked tricyclic compounds as inhibitors of protein aggregation